ABSTRACT: Background. Combined inhibition of epidermal growth factor receptor (EGFR) and insulin-like growth factor-1 receptor (IGF-1R) has been proposed as a therapy for cutaneous squamous cell carcinoma of the head and neck (SCCHN). Methods. Receptor expression and downstream signaling were assessed in cutaneous squamous cell carcinoma (SCC) cell lines and patient samples. EGFR and IGF-1R signaling was inhibited in cutaneous SCC cell lines using erlotinib and/or picropodophyllin. Results. EGFR and IGF-1R were overexpressed in cutaneous SCCHN specimens relative to normal skin. Dual inhibition of both receptors prevented cell growth and decreased activation of Akt and p42/44 mitogen-activated protein kinase (MAPK) more effectively than either inhibitor alone. Conclusion. Dual inhibition of EGFR and IGF-1R is effective at blocking cell growth, and is correlated with inhibition of Akt and p42/44 MAPK, suggesting that this may be a promising treatment for cutaneous SCCHN.
INTRODUCTION
Over 200,000 cases of cutaneous squamous cell carcinoma (SCC) are diagnosed each year in the United States, many of which are found on the head and neck (cutaneous SCCHN). 1 Although most are early-stage tumors and are easily treated with surgical excision, approximately 5% of patients will develop metastases. 2 Unfortunately, 10-year survival rates are <20% with lymph node metastases and <10% with distant metastases. 1 This is likely the result of patient factors, such as frequent medical comorbidities, and treatment factors including a relatively poor understanding of the molecular underpinnings of metastatic cutaneous SCC and the overall poor responsiveness of this disease to traditional therapies. 3, 4 Thus, there is increasing interest in applying targeted molecular agents for treatment of cutaneous SCC.
Epidermal growth factor receptor (EGFR) has emerged as 1 potential therapeutic target for cutaneous SCCHN. 5 EGFR is upregulated in 80% to 100% of cutaneous SCC 6, 7 and is linked to carcinogenesis in the skin and in other organs. 8 Given the effectiveness of selective EGFR inhibitors in other EGFR-expressing tumors, [9] [10] [11] EGFR inhibitors such as erlotinib, a small molecule tyrosine kinase inhibitor, and cetuximab, a monoclonal blocking antibody, have been used in patients with metastatic cutaneous SCCHN on an off-label basis and in early-phase clinical trials. However, to date there are no phase III studies directly examining their effectiveness in this patient population.
Although EGFR inhibitors have shown promise in a variety of tumor types, their use is often limited by the rapid development of resistance. 12 In other tumor types, resistance to EGFR inhibitors has been shown to occur through increased signaling via insulin-like growth factor-1 receptor (IGF-1R). [13] [14] [15] [16] Subsequent inhibition of IGF-1R can overcome resistance to EGFR inhibitors. Recently, dual inhibition of EGFR and IGF-1R using blocking antibodies was shown to prevent the growth of human cutaneous SCC cells in culture and in mouse xenografts models. 17 However, no in vivo data exists from patient specimens to indicate that IGF-1R is involved in cutaneous SCC resistance to EGFR inhibitors or that inhibition of IGF-1R in combination with EGFR may benefit patients with advanced cutaneous SCC. Furthermore, the effectiveness of small molecule EGFR inhibitors, rather than monoclonal blocking antibodies, has not yet been established in cutaneous SCCHN. Small molecule IGF-1R inhibitors are currently being investigated. One such inhibitor, picropodophyllin (PPP), is well tolerated in vivo; in some animal studies, it has been tolerated for several months of daily treatment without any adverse effects noted. 18 It is highly specific for IGF-1R and does not significantly inhibit the insulin receptor, a potential doselimiting effect of less specific IGF-1R inhibitors. 19 While limited human data exist to confirm the importance of avoiding inhibition of the insulin receptor, PPP has shown use in treating several tumor types in experimental systems including uveal melanoma, 20, 21 multiple myeloma, 18 osteosarcoma, 22 and glioblastoma. 23 In this study, our purpose was to explore the role of EGFR and IGF-1R signaling pathways in human cutaneous SCCHN and to assess the effect of dual inhibition of IGF-1R and EGFR with small molecule tyrosine kinase inhibitors on cutaneous SCC.
MATERIALS AND METHODS

Cell lines and reagents
SCC12 and SCC13 cell lines, derived from head and neck primary cutaneous SCC, were obtained from Dr. James Rheinwald. 24 Creation of the MET1 and MET4 cell lines, derived from a forearm cutaneous SCC and its associated lymph node metastasis, respectively, has been previously described. 25 All cells were grown in HDMEM (Invitrogen, Carlsbad, CA) supplemented with 10% fetal bovine serum in a humidified 5% CO 2 incubator at 37 C. Erlotinib was purchased from Selleck Chemicals (Houston, TX). PPP was purchased from Enzo Life Sciences (Farmingdale, NY).
Cell proliferation assays
MET1, MET4, SCC12, or SCC13 cells were plated at a density of 5000 cells per well in 96-well plates. Varying concentrations of erlotinib or PPP, spanning physiologic doses previously shown to inhibit other tumor types in cell culture, were added and cells were cultured for 48 hours. 12, 26, 27 The (4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (methyl thiazolyl-tetrazolium [MTT]) assays (Promega, Madison WI) were performed in triplicate, according to the manufacturer's protocol. The absorbance at 570 nM in each well was measured using a Spectramax Plus plate reader (Molecular Devices, Sunnyvale, CA).
Receptor phosphorylation status by enzyme-linked immunosorbent assay (ELISA) MET1, MET4, SCC12, and SCC13 cells were individually plated at a density of 50,000 cells per well in 6-well plates. Vehicle control, 500 nM erlotinib, 150 nM PPP, or both inhibitors were added to the cells. The cells were grown for 48 hours, and then harvested into DuoSet IC lysis buffer (R&D Systems, Minneapolis, MN). Enzymelinked immunoserbent assay (ELISA) assays were then performed according to the manufacturer's protocol. The absorbance of each well at 450 nM was determined using a Spectramax Plus plate reader (Molecular Devices). All assays were performed in triplicate.
Signaling assays MET1, MET4, SCC12, and SCC13 cells were grown as described for ELISA, but were harvested into Laemmli protein sample buffer. Samples were run on sodium dodecyl sulfate-polyacrylamide gel electrophoresis gels, transferred to nitrocellulose membranes, and then incubated with primary antibodies. The following antibodies were used at the listed concentrations, all from Cell Signaling (Danvers, MA): EGFR (1:1000), phospho-EGFR (1:1000), IGF-1R b subunit (1:1000), phospho-IGF-1R b subunit (1:2000), Akt (1:2000), Ser473 phospho-Akt (1:1000), p44.42 mitogen-activated protein kinase (MAPK; 1:1000), Thr202/Tyr204 phospho-p44/42 MAPK (1:1000), mammalian target of rapamycin (mTOR; 1:2000), Ser2448 phospho-mTOR (1:1000). The membranes were washed, and incubated with either Alexa Fluor 680 anti-mouse (Molecular Probes, Carlsbad, CA) or Fluor 800 anti-rabbit (Li-Cor, Lincoln, NE), and then imaged using a Li-Cor Odyssey Scanner (Li-Cor). Quantification was performed using Li-Cor analysis software (Li-Cor) and expression levels were normalized to atubulin.
Patient samples
Patients treated with cutaneous SCC at Oregon Health and Science University in the departments of dermatology and otolaryngology/head and neck surgery over the last 10 years have been enrolled in a research tumor bank. This tissue bank also houses normal skin specimens. This tumor bank and associated studies were approved by the Oregon Health and Science University institutional review board. Nine cutaneous SCCHN and normal-appearing skin specimens from the same patients were selected for use in this study.
Immunofluorescence
Formalin-fixed, paraffin-embedded, 5-lm-thick tissue sections were evaluated with antibodies using standard conditions 28 and antigen retrieval (10 mmol/L citrate buffer, pH 6, or 10 mmol/L Tris/1 mmol/L ethylenediaminetetraaceticacid, pH 9, at 100 C for 50 minutes). Tissue sections were incubated with the following primary antibodies overnight at 4 C at 1:300 dilution: EGFR (Cell Signaling), IGF-1R (Santa Cruz Biotechnology, Santa Cruz, CA), and pan-cytokeratin (Fitzgerald, Acton, MA). Visualization was facilitated by fluorescent detection of Cy5-conjugated (1:1000; Jackson Immunoresearch, West Grove, PA), Alex Fluor 546-conjugated (1:1000; Molecular Probes), or Alexa Fluor 488-conjugated (1:1000; Molecular Probes) secondary antibodies and the nuclear stain Hoescht 33258 (100 ng/mL; Sigma-Aldrich, St. Louis, MO) using a Leica confocal microscope (Leica Microsystems, Wetzlar, Germany) and identical settings across all slides.
Quantification of fluorescence
Immunofluorescent images were captured with separate lasers using fluoview FV1000 software (Olympus, Center Valley, PA). CellProfiler software 29 was used to determine expression of EGFR and IGF-1R in cutaneous SCC cells. Briefly, the software was configured using a reference image to identify cytokeratin-positive cells in the image as cutaneous SCC cells. Thresholds were then set for positive EGFR or IGF-1R expression such that the CellProfiler correctly identified cells within the reference image that a trained observer would also score as positively expressing cells. All images were subsequently processed using the defined thresholds and the percentage of cytokeratin-positive cells expressing either EGFR or IGF-1R was reported.
Statistics
Analysis of variance and t test were performed using GraphPad Prism (GraphPad Software, San Diego, CA) to determine statistical significance with a p value < .05 indicating significance. Erlotinib and PPP IC50 values for all cell lines were determined by curve fitting MTT assay absorbance values across the full range of inhibitor concentrations tested using Kaliedagraph (Synergy Software, Redding, PA), and then solving the resulting curve equation for a 50% response.
RESULTS
Although there is substantial evidence that EGFR is overexpressed in cutaneous SCC, there is little data examining IGF-1R expression in human cutaneous SCCHN tumors. Thus, pathologic specimens of normal-appearing skin and primary cutaneous SCCHN were evaluated for EGFR and IGF-1R expression by immunofluorescent FIGURE 1. Epidermal growth factor receptor (EGFR) and insulin-like growth factor-1 receptor (IGF-1R) protein expression in cutaneous squamous cell carcinoma (SCC). A, Pathologic specimens of normal skin and primary cutaneous SCC were sectioned and immunofluorescence labeling performed with antibodies specific for EGFR (red) and IGF-1R (yellow). Pan-cytokeratin (green) is also shown to demonstrate the distribution of cutaneous SCC cells. Nuclei were detected using diamidino-phenylindole (DAPI) staining, shown in the cytokeratin and merged images; Bar ¼ 50 lm. EGFR and IGF-1R were overexpressed in cutaneous SCC samples. B, Schematic of skin morphology is superimposed over an image of cytokeratin immunofluorescence from a specimen of normal skin. The dashed line is drawn over the epidermal/dermal junction, with the basal cell layer sitting immediately superficial to this junction. C, EGFR and IGF-1R expression was quantified using CellProfiler by determining the percentage of cutaneous SCC cells expressing EGFR or IGF-1R (*denotes p < .05 between normal skin and cutaneous SCC). A highly significant 3-fold increase in EGFR was seen in cutaneous SCC samples compared to normal skin (p ¼ .00077), and a smaller but significant upregulation of IGF-1R in cutaneous SCC samples was also observed (p ¼ .041).
analysis ( Figure 1A) . Consistent with previous reports, 30 morphologic analysis showed that EGFR was primarily expressed in the basal cell layer of the epidermis in normal skin ( Figure 1B) . In contrast, EGFR was expressed more widely in cutaneous SCCHN, with approximately 3-fold more expression than normal-appearing skin ( Figure  1C ). IGF-1R was distributed throughout the epidermis at low levels in normal skin, and was upregulated approximately 50% in cutaneous SCCHN samples, including in many EGFR overexpressing cells. The overexpression of both receptors in cutaneous SCCHN suggests that dual inhibition of these receptors may be a useful chemotherapeutic strategy for cutaneous SCCHN.
Both erlotinib and PPP are designed to inhibit receptor autophosphorylation, the first step in receptor signaling. To assess the effect of these inhibitors on receptor phosphorylation, MET1 cells were cultured in the presence of erlotinib, PPP, or both inhibitors. Cell lysates from these cultures were then immunoblotted for phospho-EGFR, phospho-IGF-1R, and total receptor expression ( Figure  2A ). Both EGFR and IGF-1R were strongly expressed in the cell lysates, and were unchanged by the presence of either inhibitor. However, both phospho-EGFR and phospho-IGF-1R were barely detectable by immunoblotting, making it impossible to quantitate. Similar results were seen in all cutaneous SCC cell lines (MET4, SCC12, SCC13; data not shown), consistent with previous studies of EGFR and IGF-1R signaling. 17 Thus, ELISA assays for phospho-EGFR and phospho-IGF-1R were used as a more sensitive measure of receptor phosphorylation. These demonstrated significant inhibition of EGFR phosphorylation in response to erlotinib across all cell lines ( Figure 2B ), and similar decreases in IGF-1R phosphorylation in response to PPP ( Figure 2C ). Furthermore, these small molecule inhibitors were specific, with no inhibition of EGFR phosphorylation by PPP, or inhibition of IGF-1R phosphorylation by erlotinib.
In order to determine the effect of erlotinib and PPP on cutaneous SCC cell growth in vitro, MTT assays were performed on MET1 cells grown for 48 hours in varying concentrations of erlotinib or PPP that span dose ranges previously shown to inhibit other tumor types. 12, 26, 27 The number of viable cells in each culture was then compared across concentrations. Both erlotinib ( Figure 3A ) and PPP ( Figure 3B ) demonstrated dose-dependent decreases in cell proliferation with increasing concentrations, and this was also observed in MET4, SCC12, and SCC13 cell lines (data not shown). IC50 values were determined for all cell lines; these results are shown in Table 1 . Next, all cell lines were cultured for 48 hours with varying concentrations of both erlotinib and PPP in combination (Figures 3C-F) . In all cases, both erlotinib and PPP showed dose-dependent decreases in cell proliferation. At the highest concentrations, the effect of PPP seemed to be stronger than that of erlotinib, as increasing erlotinib concentrations at high levels of PPP did not alter cell proliferation. However, at some intermediate concentrations, the combination of both inhibitors seemed to cause a greater reduction in cell proliferation than either inhibitor alone, suggesting an additive action between these 2 drugs ( Table 2) .
IGF-1R signaling is hypothesized to contribute to EGFR inhibitor resistance via activation of similar FIGURE 2. Receptor phosphorylation response to small molecule inhibitors. A, MET1 cells were harvested after incubation for 48 hours in the presence of either 500 nM erlotinib or 150 nM as indicated. Cell lysates were then immunoblotted for phosphoepidermal growth factor receptor (EGFR), total EGFR, phosphoinsulin-like growth factor-1 receptor (IGF-1R), and total IGF-1R. While expression levels of the receptors did not change, the phosphorylated receptors were barely detectable by immunoblotting. Immunoblots for a-tubulin were used as loading controls. Similar results were observed in other cell lines (not shown). B, Cell lines (MET1, MET4, SCC12, and SCC13) were incubated in either 500 nM erlotinib or 150 nM as indicated. Cell lysates were then used for phospho-EGFR-specific enzymelinked immunosorbent assay (ELISA). The level of EGFR phosphorylation was normalized to the level observed in the control lysates for each cell line. Erlotinib treatment significantly reduced EGFR phosphorylation in all cell lines (*denotes p < .01 relative to control), while picropodophyllin (PPP) had no effect on EGFR phosphorylation. C, Lysates from (B) were also used for phospho-IGF-1R-specific ELISAs. In this case, PPP treatment reduced IGF-1R phosphorylation (*denotes p < .05 vs control) whereas erlotinib had no effect on IGF-1R phosphorylation.
downstream signaling cascades; however, multiple downstream signaling molecules have been implicated in this process. In order to determine which pathways may be relevant in cutaneous SCC, evaluation of the expression of phosphorylated and total Akt, p42/44 MAPK, and mTOR by immunoblotting was performed in cutaneous SCC cells treated either with erlotinib, PPP, or dual treatment ( Figure 4A ). Inhibition of Akt and p42/44 MAPK activation by both erlotinib and PPP was observed ( Figure  4B and C), while no detectable change in mTOR activation occurred. Furthermore, the combination of both EGFR and IGF-1R inhibitors resulted in a larger decrease in Akt and p42/44 phosphorylation than either inhibitor alone. Thus, inhibition of signaling via both the Akt and p42/44 MAPK pathways may be critical to EGFR and IGF-1R inhibition of tumor proliferation.
DISCUSSION
Although early-stage cutaneous SCCHN is treated well with surgical excision, patients with disease metastatic to cervical lymph nodes fare poorly. 31 There is no Food and Drug Administration-approved chemotherapy for cutaneous SCCHN with metastases. While EGFR inhibitors have emerged as potentially promising therapeutic agents for this disease, their use can be limited by the development of resistance. In non-small cell lung cancer, 1 mechanism that has been described to cause resistance to EGFR inhibitors is compensatory signaling via the IGF-1R pathway. 15, 16 Dual inhibition of EGFR and IGF-1R with blocking antibodies improves inhibition of tumor growth over either agent alone in cutaneous SCC. 17 However, the importance of IGF-1R signaling in human cutaneous SCCHN remains unclear. Thus, in this study, we aimed to explore the role of EGFR and IGF-1R signaling pathways in human cutaneous SCCHN and to assess the effect of dual inhibition of IGF-1R and EGFR with small molecule tyrosine kinase inhibitors on cutaneous SCC.
Similar to other studies, we found EGFR to be overexpressed in cutaneous SCCHN. 7, 32 We also found IGF-1R to be overexpressed in human cutaneous SCCHN samples. This is a novel finding as IGF-1R overexpression was only previously demonstrated in cultured cells. 17 The roughly 50% upregulation in IGF-1R expression in cutaneous SCCHN relative to normal skin supports the idea that signaling via this receptor may have a role in the pathogenesis of cutaneous SCCHN and may represent a valid clinical target for anti-cutaneous SCC therapy.
Whereas EGFR and IGF-1R are readily identifiable in human tissue, our difficulty in observing EGFR and IGF-1R phosphorylation in cell culture lysates using immunoblotting is not unexpected. Other studies have shown similar results in other cutaneous SCC cell lines, 17 suggesting that only a small fraction of the EGFR or IGF-1R is active at any one time. Previous studies have demonstrated the effectiveness of EGFR and IGF-1R inhibitors on receptor phosphorylation by treating cells with large doses of EGF or IGF, then applying inhibitors to block the massive increase in receptor phosphorylation that results from supraphysiologic levels of growth factors. However, we felt that artificially boosting the levels of these growth factors would not accurately reflect the in vivo tumor microenvironment. Using ELISA as a more sensitive assay, we were able to show that EGFR and IGF-1R inhibitors function as predicted in cutaneous SCC cells to block receptor signaling selectively.
Both erlotinib and PPP decreased cell growth in all cutaneous SCC cell lines studied. However, there was variability in susceptibility to these inhibitors across cell lines as evidenced by the range of IC50 values observed across cell lines. Our data also showed cooperation in preventing tumor growth between EGFR and IGF-1R inhibitors. These findings are in agreement with other studies 13, 14, 16, 17, [33] [34] [35] ; however, additive effects of erlotinib and PPP were observed only at some intermediate concentrations, whereas, at other concentrations, there was no apparent additive effect to the use of both inhibitors. Furthermore, the addition of erlotinib to high concentrations of PPP did not alter cell growth. The reasons for this are unknown but may be due, in part, to the well-known properties of biologic agents as cytostatic rather than cytotoxic agents. [33] [34] [35] [36] Alternatively, this may result from the milleu of growth factors present in our cell culture media relative to that present in vivo. As the particular mix of growth factors present in the tumor microenvironment is currently unknown, the relative importance of each signaling pathway in cell culture may not accurately reflect the in vivo situation.
We found that dual inhibition of EGFR and IGF-1R resulted in inhibition of downstream signaling. Specifically, we identified Akt and MAPK inhibition after treatment with EGFR and IGF-1R inhibitors. This is not surprising given similar results reported after treatment with EGFR inhibitors alone. For example, in breast cancer, 37 non-small cell lung cancer, 38 and head and neck SCC, 39 genfitinib was shown to decrease activation of both Akt and p42/44 MAPK. Furthermore, cells resistant to genfitinib have increased levels of phosphorylated Akt and p42/ 44 MAPK. Increased Akt phosphorylation has also been linked to erlotinib resistance. 27 In cutaneous SCC, genfitinib has been shown to inhibit p42/44 MAPK signaling, 40 and EGFR inhibition decreases Akt signaling. 41 Inhibition of IGF-1R can also prevent Akt and p42/44 MAPK phosphorylation. 42 Targeting of these signaling intermediates may also serve as a potential therapy for cutaneous SCC; indeed, a recent study showed that combined inhibition of EGFR and PI3K/Akt signaling improved growth inhibition of cutaneous SCC cells. 43 Therefore, it is possible that the Akt and/or the p42/44 MAPK pathway serve as a common final pathway by which IGF-1R activation leads to EGFR inhibitor resistance.
In summary, we have shown that EGFR and IGF-1R are overexpressed in cutaneous SCC, and that dual inhibition of these receptors using tyrosine kinase inhibitors improves tumor growth inhibition. Our data suggest that either Akt or p42/44 MAPK may be the common intermediate linking these signaling pathways, although further work will be needed to decisively link Akt and/or p42/44 MAPK to EGFR and IGF-1R signaling in cutaneous SCC. Together with previously published data, this provides strong support for dual EGFR and IGF-1R inhibition as a new therapeutic modality for advanced cutaneous SCC and lays the foundation for future clinical trials to investigate this possibility.
